Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3926480 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1MEN1KMT2AOPRD1 | |
| SCHEMBL3925521 | 0.87 | KCNH2 (0.48) | ALDH1A1MEN1KMT2AL3MBTL1 | |
| Maleic Acid SCHEMBL25236759 | 0.78 | ALDH1A1 (0.62) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL28710506 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1MEN1KMT2AOPRD1 | |
| Fumaric Acid SCHEMBL9081893 | 0.73 | ALDH1A1 (0.60) | KDM4EALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL10417628 | 0.72 | ALDH1A1 (0.50) | ALDH1A1KMT2A | |
| SCHEMBL81625 | 0.71 | LMNA (0.63) | ALDH1A1MEN1KMT2AHSP90AA1L3MBTL1 | |
| Benzene SCHEMBL27902631 | 0.71 | LMNA (0.63) | ALDH1A1MEN1KMT2AHSP90AA1L3MBTL1 | |
| SCHEMBL29558711 | 0.71 | ALDH1A1 (0.45) | KDM4EALDH1A1MEN1KMT2AOPRD1 | |
| SCHEMBL4760461 | 0.71 | ALDH1A1 (0.45) | KDM4EALDH1A1MEN1KMT2AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865210-B2 | Stable dosage formulations of imidazolylalkyl-pyridines | VANDA PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | claimed |
| WO-2009097414-A1 | USE OF IMIDAZOLYLALKYL-PYRIDINES FOR THE TREATMENT OF ADDICTIVE DISORDERS | VANDA PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | claimed |
| EP-1919477-A4 | METHOD OF IMPROVING WAKEFULNESS | VANDA PHARMACEUTICALS INC (US) | 2009-03-18 | — | — | EP | claimed |
| US-20090011011-A1 | STABLE DOSAGE FORMULATIONS OF IMIDAZOLYLALKYL-PYRIDINES | VANDA PHARMACEUTICALS, INC. | 2009-01-08 | — | — | US | claimed |
| US-20080280954-A1 | Method of Improving Wakefulness | VANDA PHARMACEUTICALS, INC (US) | 2008-11-13 | — | — | US | claimed |
| EP-1986659-A2 | STABLE DOSAGE FORMULATIONS OF IMIDAZOLYLALKYL-PYRIDINES | Vanda Pharmaceuticals Inc. (US) | 2008-11-05 | — | — | EP | claimed |
| EP-1919477-A1 | METHOD OF IMPROVING WAKEFULNESS | Vanda Pharmaceuticals Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2007095523-A2 | STABLE DOSAGE FORMULATIONS OF IMIDAZOLYLALKYL-PYRIDINES | VANDA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | WO | claimed |
| WO-2007016203-A1 | METHOD OF IMPROVING WAKEFULNESS | VANDA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | WO | claimed |
| US-20060258717-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-16 | — | — | US | claimed |
| EP-1718302-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-11-08 | — | — | EP | claimed |
| WO-2005074926-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | claimed |
| US-5856343-A | Imidazolylmethyl-pyridines used for senile dementia | NOVARTIS AG (CH) | 1999-01-05 | — | — | US | claimed |
| US-5635521-A | DRUGS TREATING ALZHEIMER'S DISEASE | SANDOZ LTD. (CH) | 1997-06-03 | — | — | US | claimed |
| US-8865210-B2 | Stable dosage formulations of imidazolylalkyl-pyridines | VANDA PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20090011011-A1 | STABLE DOSAGE FORMULATIONS OF IMIDAZOLYLALKYL-PYRIDINES | VANDA PHARMACEUTICALS, INC. | 2009-01-08 | — | — | US | disclosed |
| EP-1986659-A2 | STABLE DOSAGE FORMULATIONS OF IMIDAZOLYLALKYL-PYRIDINES | Vanda Pharmaceuticals Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007095523-A2 | STABLE DOSAGE FORMULATIONS OF IMIDAZOLYLALKYL-PYRIDINES | VANDA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258717-A1 | ORGANIC COMPOUNDS | VEGFA, FLT4, FLT1 | MEN1 826/4885KMT2A 1618/4885KDM4E 892/4885 |
| US-20080280954-A1 | Method of Improving Wakefulness | PNMT, HCRTR2, HCRTR1 | MEN1 3821/4885KMT2A 159/4885KDM4E 190/4885 |
| US-20090011011-A1 | STABLE DOSAGE FORMULATIONS OF IMIDAZOLYLALKYL-PYRIDINES | CYP2C19, SLC18A1, PLPBP | MEN1 1609/4885KMT2A 3886/4885KDM4E 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.